Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544
Recruiting
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/11/2023
Locations: Sunpharma Site no 34, Greenville, South Carolina
Conditions: Active Psoriatic Arthritis
Register for Updates
A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis
NCT05197036
Recruiting
A clinical trial investigating the safety and effectiveness of Smith and Nephew's FDA-approved Porous Total Knee System, which is used to replace worn away and diseased knee joints. The aim of this study is to show that most patients who receive the Porous Total Knee System have reduced pain, greater mobility and a long-lasting implant post-surgery.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/10/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Sunpharma site no 31, Greenville, South Carolina
Conditions: Psoriatic Arthritis
Register for Updates
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531
Recruiting
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
Gender:
All
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: Sunpharma site no. 11, Greenville, South Carolina
Conditions: Active Psoriatic Arthritis
Register for Updates
A Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Knee Osteoarthritis Pain.
NCT05025787
Recruiting
The primary objective of this study is to evaluate the safety and efficacy of CNTX-6970 for the treatment of pain related to OA of the knee compared to placebo. CNTX-6970 is being developed as a new treatment for chronic pain, including painful osteoarthritis of the knee.
Gender:
All
Ages:
Between 40 years and 90 years
Trial Updated:
10/31/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Knee Osteoarthritis
Register for Updates
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292
Recruiting
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Coastal Carolina Research Center, North Charleston, South Carolina
Conditions: Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Register for Updates
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Tribe Clinical Research, LLC, Greenville, South Carolina +1 locations
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Articularis Healthcare d/b/a/ Low Country Rheumatology, PA, Summerville, South Carolina
Conditions: Rheumatoid Arthritis
Register for Updates
A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee
NCT03754049
Recruiting
This study is a multi-center, Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with OA of the knee enrolled to receive single-dose of TLC599 or DSP via IA injection and 1 cohort of healthy subjects to receive single-dose of DSP via IV injection.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: Clinical Trials of South Carolina, Charleston, South Carolina
Conditions: OSTEOARTHRITIS OF THE KNEE
Register for Updates
Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee
NCT05449132
Recruiting
A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: PCPMG Clinical Research Unit, LLC, Greenville, South Carolina +1 locations
Conditions: Osteoarthritis
Register for Updates
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee
NCT03203330
Recruiting
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficac... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
09/25/2023
Locations: Edward Tavel, Columbia, South Carolina
Conditions: Degenerative Osteoarthritis
Register for Updates
Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee
NCT03291470
Recruiting
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficac... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
09/25/2023
Locations: Edward Tavel, Charleston, South Carolina
Conditions: Degenerative Osteoarthritis
Register for Updates